Associated Genetic Biomarkers
MPL proto-oncogene, thrombopoietin receptor (MPL) is a gene that encodes a protein that resembles members of the hematopoietic receptor superfamily. Missense, nonsense, and silent mutations are observed in cancers such as colorectal cancer, leukemias, lung cancer, and skin cancer.
MPL is altered in 1.24% of all cancers with lung adenocarcinoma, colon adenocarcinoma, cutaneous melanoma, breast invasive ductal carcinoma, and endometrial endometrioid adenocarcinoma having the greatest prevalence of alterations .
The most common alterations in MPL are MPL Mutation (1.04%), MPL Amplification (0.20%), MPL Exon 10 Mutation (0.13%), MPL W515L (0.19%), and MPL Loss (0.04%) .
MPL status serves as an inclusion eligibility criteria in 3 clinical trials, of which 2 are open and 1 is closed. Of the trials that contain MPL status as an inclusion criterion, 1 is phase 1/phase 2 (1 open) and 2 are phase 2 (1 open).
Trials with MPL status in the inclusion eligibility criteria most commonly target acute myeloid leukemia, myelodysplastic syndrome with excess blasts-2, myelofibrosis, myeloid neoplasm, and secondary acute myeloid leukemia .
The most frequent alteration to serve as an inclusion eligibility criterion is MPL Mutation .
Allogeneic hematopoietic stem cell transplantation, liposome-encapsulated daunorubicin-cytarabine, busulfan, cyclophosphamide, and fludarabine are the most frequent therapies in trials with MPL as an inclusion criteria .
Significance of MPL in Diseases
Myeloid Neoplasm +
Acute Myeloid Leukemia +
Multiple Myeloma +
Myelodysplastic Syndrome With Excess Blasts-2 +
MPL is an inclusion criterion in 1 clinical trial for myelodysplastic syndrome with excess blasts-2, of which 1 is open and 0 are closed. Of the trial that contains MPL status and myelodysplastic syndrome with excess blasts-2 as inclusion criteria, 1 is phase 2 (1 open) .
Plasma Cell Leukemia +
MPL is an inclusion criterion in 1 clinical trial for plasma cell leukemia, of which 0 are open and 1 is closed. Of the trial that contains MPL status and plasma cell leukemia as inclusion criteria, 1 is phase 2 (0 open) .
Secondary Acute Myeloid Leukemia +
MPL is an inclusion criterion in 1 clinical trial for secondary acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains MPL status and secondary acute myeloid leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) .
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.